Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Melisi

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Frontiers in Oncology|May 12, 2020
Permissive State of EMT: The Role of Immune Cell CompartmentVita Fedele, Davide Melisi
Expert Opinion on Therapeutic Targets|March 27, 2012
NF-κB as a target for pancreatic cancer therapyCarmine Carbone, Davide Melisi
Current Drug Targets|March 31, 2012
Pancreatic cancer: between bench and bedsideDavide Melisi, Alfredo Budillon
Cellular and Molecular Gastroenterology and Hepatology|June 28, 2021
A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to SorafenibSilvia Pietrobono, Davide Melisi
Expert Opinion on Therapeutic Targets|January 18, 2007
NF-kappa B as a target for cancer therapyDavide Melisi, Paul J Chiao
Cancers|September 13, 2017
EMT and Treatment Resistance in Pancreatic CancerNicola Gaianigo, Davide Melisi, Carmine Carbone
Future Oncology (London, England)|October 9, 2020
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinomaValeria Merz, Camilla Zecchetto, Davide Melisi
Cancer Treatment Reviews|March 26, 2026
Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunitiesEnza Scarlato, Nelson Dusetti, Davide Melisi
Current Pharmaceutical Design|February 3, 2004
Angiogenesis: a target for cancer therapyGiampaolo Tortora, Davide Melisi, Fortunato Ciardiello
Cancers|November 11, 2020
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic TherapiesSerena Contarelli, Vita Fedele, Davide Melisi
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Frontiers in Oncology|May 12, 2020
Permissive State of EMT: The Role of Immune Cell CompartmentVita Fedele, Davide Melisi
Expert Opinion on Therapeutic Targets|March 27, 2012
NF-κB as a target for pancreatic cancer therapyCarmine Carbone, Davide Melisi
Current Drug Targets|March 31, 2012
Pancreatic cancer: between bench and bedsideDavide Melisi, Alfredo Budillon
Cellular and Molecular Gastroenterology and Hepatology|June 28, 2021
A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to SorafenibSilvia Pietrobono, Davide Melisi
Expert Opinion on Therapeutic Targets|January 18, 2007
NF-kappa B as a target for cancer therapyDavide Melisi, Paul J Chiao
Cancers|September 13, 2017
EMT and Treatment Resistance in Pancreatic CancerNicola Gaianigo, Davide Melisi, Carmine Carbone
Future Oncology (London, England)|October 9, 2020
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinomaValeria Merz, Camilla Zecchetto, Davide Melisi
Cancer Treatment Reviews|March 26, 2026
Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunitiesEnza Scarlato, Nelson Dusetti, Davide Melisi
Current Pharmaceutical Design|February 3, 2004
Angiogenesis: a target for cancer therapyGiampaolo Tortora, Davide Melisi, Fortunato Ciardiello
Cancers|November 11, 2020
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic TherapiesSerena Contarelli, Vita Fedele, Davide Melisi
Pageof 13